Theravance Biopharma, Inc. TBPH · Stock Open Theravance Biopharma, Inc. in new tab
Analyst price targets
Recent rating changes, newest first
Theravance Biopharma, Inc. Analysis (TBPH)
Is Theravance Biopharma, Inc. a good investment? Theravance Biopharma, Inc. (TBPH) is currently trading at 17.03 USD. Market analysts have a consensus price target of 17.67 USD. This suggests a potential upside from current levels.
In terms of valuation, the stock trades at a P/E ratio of 16.38. This valuation is generally in line with the broader market.
Earnings Schedule: Theravance Biopharma, Inc. is expected to release its next earnings report on Nov. 10, 2026. The market consensus estimate for Forward EPS is 1.28.
Investor FAQ
Does Theravance Biopharma, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Theravance Biopharma, Inc.?
Theravance Biopharma, Inc. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be Nov. 10, 2026. The company currently has a trailing EPS of 1.04.
Company Profile
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California. As of September 23, 2026, Theravance Biopharma, Inc. operates as a subsidiary of Zymeworks Inc.
Community Discussion